Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Hydroxyaldimines as potent in vitro anticryptococcal agents.

Magalhães TF, da Silva CM, de Fátima Â, da Silva DL, Modolo LV, Martins CV, Alves RB, Ruiz AL, Longato GB, de Carvalho JE, de Resende-Stoianoff MA.

Lett Appl Microbiol. 2013 Aug;57(2):137-43. doi: 10.1111/lam.12086. Epub 2013 May 20.

2.

Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.

Morales BP, Junior IN, Trilles L, Bertho AL, Oliveira Rde V, Nishikawa MM, Elias Mdos S, Wanke B, Lazéra Mdos S.

Med Mycol. 2014 Jan;52(1):90-8. doi: 10.3109/13693786.2013.806827.

PMID:
23808405
3.
4.

Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro.

Pereira de Sá N, Lino CI, Fonseca NC, Borelli BM, Ramos JP, Souza-Fagundes EM, Rosa CA, Santos DA, Barbosa de Oliveira R, Johann S.

Eur J Med Chem. 2015 Sep 18;102:233-42. doi: 10.1016/j.ejmech.2015.07.032. Epub 2015 Jul 17.

PMID:
26276437
5.

Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.

Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML.

Med Mycol. 2013 Aug;51(6):635-40. doi: 10.3109/13693786.2012.761737. Epub 2013 Jan 23.

PMID:
23343452
6.

Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.

Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A.

Braz J Microbiol. 2015 Oct-Dec;46(4):1125-33. doi: 10.1590/S1517-838246420140564. Epub 2015 Oct 27.

7.

In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.

Del Poeta M, Bixel AS, Barchiesi F, Tidwell RR, Boykin D, Scalise G, Perfect JR.

J Antimicrob Chemother. 1999 Aug;44(2):223-8.

PMID:
10473229
8.

In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Chong HS, Dagg R, Malik R, Chen S, Carter D.

J Clin Microbiol. 2010 Nov;48(11):4115-20. doi: 10.1128/JCM.01271-10. Epub 2010 Sep 15.

9.

[First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].

Favalessa OC, Ribeiro LC, Tadano T, Fontes CJ, Dias FB, Coelho BP, Hahn RC.

Rev Soc Bras Med Trop. 2009 Nov-Dec;42(6):661-5. Portuguese.

10.

Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B.

de Aguiar Cordeiro R, Mourão CI, Rocha MF, de Farias Marques FJ, Teixeira CE, de Oliveira Miranda DF, Neto LV, Brilhante RS, de Jesus Pinheiro Gomes Bandeira T, Sidrim JJ.

Eur J Clin Microbiol Infect Dis. 2013 Apr;32(4):557-64. doi: 10.1007/s10096-012-1774-8. Epub 2012 Nov 29.

PMID:
23192488
11.

In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.

Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J.

J Med Microbiol. 2011 Jul;60(Pt 7):961-7. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10.

PMID:
21393452
12.

In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.

Morales BP, Trilles L, Bertho ÁL, Junior IN, de Oliveira Rde V, Wanke B, Lazéra Mdos S.

Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.

PMID:
25756839
13.

In vitro susceptibility of Cryptococcus gattii clinical isolates.

Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M.

Clin Microbiol Infect. 2008 Jul;14(7):727-30. doi: 10.1111/j.1469-0691.2008.02021.x.

15.

Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.

Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M.

Med Mycol. 2012 Apr;50(3):328-32. doi: 10.3109/13693786.2011.602126. Epub 2011 Aug 23.

PMID:
21859388
16.

Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.

Matos CS, de Souza Andrade A, Oliveira NS, Barros TF.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1647-52. doi: 10.1007/s10096-011-1488-3. Epub 2012 Jan 26.

17.

[Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].

Fernández Andreu CM, Pimentel Turino T, Martínez Machín G, González Miranda M.

Rev Cubana Med Trop. 1999 Jan-Apr;51(1):55-7. Spanish.

PMID:
10887558
18.

Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.

Mendes FE, Oliveira LV, Faria ES, Alvarenga DG, Pinto MR, Taborda CP, Soares BM, Cisalpino PS, Santos DA.

Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1525-32. doi: 10.1007/s10096-010-1034-8. Epub 2010 Aug 28.

PMID:
20803047
19.

Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.

Khan ZU, Randhawa HS, Chehadeh W, Chowdhary A, Kowshik T, Chandy R.

Int J Antimicrob Agents. 2009 Jun;33(6):559-63. doi: 10.1016/j.ijantimicag.2008.11.007. Epub 2009 Feb 4.

PMID:
19195846
20.

Supplemental Content

Support Center